RECOVERY Trial Finds No Benefit of Colchicine in Hospitalised COVID-19 Patients

Pavankumar Kamat

Disclosures

October 22, 2021

Takeaway

  • Colchicine plus standard of care (SOC) vs SOC alone had no significant effect on all-cause mortality, probability of being discharged alive within 28 days, and the risk of progressing to invasive mechanical ventilation or death among patients hospitalised with SARS-CoV-2 infection.

Why this matters

  • Findings do not support the use of colchicine with SOC in hospitalised patients with COVID-19.

Study details

  • The RECOVERY trial randomly assigned 11,340 hospitalised patients (from 177 UK hospitals and 2 hospitals each in Nepal and Indonesia [n=36]) with suspected or laboratory-confirmed SARS-CoV-2 infection to receive SOC with (n=5610) or without (n=5730) colchicine.

  • Primary outcome: all-cause mortality at 28 days.

  • Funding: UK Research and Innovation (Medical Research Council), National Institute for Health Research and Wellcome Trust.

Key results

  • All-cause mortality at 28 days was similar between SOC and SOC+colchicine groups (21% vs 21%; rate ratio, 1.01; 95% CI, 0.93-1.10; P=.77).

  • The discharge rate of alive patients at 28 days was also similar between SOC and SOC+colchicine groups (70% vs 70%; rate ratio, 0.98; 95% CI, 0.94-1.03; P=.44).

  • Among patients who were not on invasive mechanical ventilation at baseline, the proportion of those progressing to the composite outcome of invasive mechanical ventilation or death was not different between SOC and SOC+colchicine groups (25% vs 25%; risk ratio, 1.02; 95% CI, 0.96-1.09; P=.47).

Limitations

  • Open-label design.

  • Information on laboratory markers of inflammation and immune response and radiological features was missing.

 

RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021 Oct 18. doi: 10.1016/ S2213-2600(21)00435-5  View full text

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....